Ahmedabad-based Lincoln Pharmaceuticals has filed a patent for its new product 'Nam Safe'. The new product is a combination of the pain killer nimesulide with methionine. |
The company plans to invest over Rs 5 crore in its research and development in next one year for new formulations. |
|
"Nam Safe is introduced for first time in the world and we are confident to get the patent soon. Our research and development (R&D) team have been working for the product for the past two years. The company is constantly giving more thrust on R&D in formulation with good numbers of scientists are constantly working on various formulations. We will first launch the product in India and then in other markets." Mahendra G Patel, managing director, Lincoln Pharma told Business Standard. |
|
The company targets a turnover of over Rs 50 crore by the end of the current financial year. With the launch of new formulation, the company aims a growth of over 15 per cent in its turn over. |
|
The company has two different manufacturing facilities for betalactum and non-betalactgurm production. The company's Khatraj plant produces only non betalactum products of tablets, capsules, liquid and drypowder, injectables and syrups. |
|
|
|